NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Kyntra Bio, Inc. (KYNB) Stock Analysis

Kyntra Bio, Inc. (KYNB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

KYNB

$5.21

−$0.07 (−1.33%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KYNB with… →

KYNB Key Statistics

As of Oct 21, 2026
Trading
Open
$5.34
Previous Close
$5.28
Day's Range
5.16–5.34
52-Week Range
4.85–11.65
Volume
11.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.05
Valuation
Market Cap
$21.10M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.57
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.64
Financials (FY)
Revenue (FY)
$6.44M−78.26%
Net Income (FY)
$183.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
3,968.63%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
4.05M
1-Year Return
−53.27%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
19.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, KYNB closed at $5.21, −53.27% over 1 year.

Kyntra Bio, Inc. (KYNB) has a market capitalization of $21.10M.

In fiscal 2025, KYNB reported revenue of $6.44M.

KYNB Stock Return by Calendar Year

Kyntra Bio, Inc. (KYNB) 10-year return: what $10,000 became

1 year
$10,000 $4,673
−53.27%
5 years
$10,000 $197
−98.03%
10 years
$10,000 $120
−98.80%

If you had invested $10,000 in Kyntra Bio, Inc. (KYNB) 10 years ago, at the close on October 21, 2016, it would have been worth $120 at the close on October 21, 2026: −98.80% in total, −35.76% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−40.66%
2025−33.74%
2024−40.18%
2023−94.47%
2022+13.62%
2021−61.98%
2020−13.52%
2019−7.32%
2018−2.36%
2017+121.50%
2016 (partial year)+9.91%

As of October 21, 2026.

KYNB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.44M$183.45M2,848.6%
2024$29.62M−$47.58M−160.6%
2023$46.80M−$284.23M−607.3%
2022$140.73M−$293.65M−208.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.44M$5.88M−$45.34M$183.45M2,848.6%
2024$29.62M$14.06M−$130.96M−$47.58M−160.6%
2023$46.80M$42.84M−$310.12M−$284.23M−607.3%
2022$140.73M$120.45M−$301.03M−$293.65M−208.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KYNB Valuation vs Biotechnology Median

Median of 608 stocks
MetricKYNBBiotechnology medianvs median
P/S ratio4.5713.3066% below
Profit margin3,968.63%−38.31%4,006.9 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kyntra Bio, Inc. (KYNB) is capitalised at $21.10M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 34 employees.

The 52-week range on file runs from $4.85 to $11.65. KYNB last closed at $5.21 on October 21, 2026. That is −$0.07 (−1.33%) against the previous close. The latest close sits 7.42% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $6.44M. That is −78.26% against the prior fiscal year, when revenue was $29.62M. The same year closed with net income of $183.45M. Profit margin runs at 3,968.63%. That is 4,006.9 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −7.64.

Across the 4 fiscal years on file, revenue moves from $140.73M in 2022 to $6.44M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 4.57. On price-to-sales that is 65.63% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −53.27%. Measured over 10 years, that is −35.76% a year compounded. The reported beta is 1.05. Daily returns over the trailing 10 years annualize to a volatility of 87.29%.

Growth & Income

No dividend is on file for KYNB.

So far in 2026 the total return is −40.66%. The strongest complete calendar year on file is 2017 at +121.50%; the weakest is 2023 at −94.47%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

Kyntra Bio, Inc. (KYNB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kyntra Bio, Inc. KYNB $21.10M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Kyntra Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Kyntra Bio, Inc.

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Visit website →